Boston Scientific Corporation (NYSE:BSX) is considered one of the best medical technology stocks to invest in. RBC Capital lowered its price target on BSX to $115 from $130 on February 6, citing weaknesses in the electrophysiology business and missed quarterly expectations.

Quarterly revenue for Boston Scientific reached $5.29 billion, with a 12.7% organic year-over-year growth. Adjusted EPS were $0.80, slightly exceeding Wall Street expectations. Bernstein SocGen also lowered its price target on BSX to $112 from $130 due to missed sales in electrophysiology and Watchman products.

The upcoming CHAMPION-AF trial results on March 28 are crucial for Boston Scientific’s stock performance. The company develops and manufactures medical devices in various specialties, including cardiology and neuromodulation, offering growth opportunities despite recent sales challenges.

Bernstein sees significant upside potential for BSX at a 21.5x valuation due to growth opportunities in electrophysiology. While BSX shows promise as an investment, other AI stocks may offer greater upside potential and lower downside risk, particularly those benefiting from tariffs and onshoring trends.

Read more at Yahoo Finance: Boston Scientific Corporation (BSX) Maintains Analyst Ratings Amid Target Adjustments